A Phase 3 interventional study of Guselkumab and Placebo in Plaque Psoriasis and Scalp Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 94 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.
Among the 29 studies testing guselkumab in Psoriasis, this one is the 10th largest by enrollment, is one of 2 that started in 2022, is one of 12 in phase 3, and was the 21st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Fondazione Policlinico Universitario Campus Bio-Medico · Sites in Italy
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 120 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 31st largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2022, is one of 36 in phase 3, and was the 63rd registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
3 of the studies testing guselkumab in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004727NYU Langone HealthMulti-Center PAMPA Study | 2026-12-31 |
| NCT07532486Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis | 2027-07-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing guselkumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive either guselkumab subcutaneously (SC) or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
Drug: Guselkumab · Drug: Placebo
Participants will receive either guselkumab SC or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
Drug: Guselkumab · Drug: Placebo
Participants will receive guselkumab as subcutaneous injection.
Also known as: CNTO1959, Tremfya
Participants will receive placebo as subcutaneous injection.
Cohort A: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation; 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.
Time frame: Week 16
Cohort A: Percentage of Participants Who Achieved Psoriasis Area Severity Index (PASI) 90 Response at Week 16
Percentage of participants who achieved PASI 90 response (greater than or equal to \[\>=\] 90 percent \[%\] improvement from baseline in PASI) at Week 16 was reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe and 4=very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Week 16
Cohort B: Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) or Very Mild Disease (1) at Week 16
The ss-IGA instrument was used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness which was scored as: absence of disease = 0, very mild disease = 1, mild disease = 2, moderate disease = 3, and severe disease = 4. A higher score indicated more severe disease.
Time frame: Week 16
Cohort B: Percentage of Participants Who Achieved Psoriasis Scalp Severity Index (PSSI) 90 Response at Week 16
PSSI 90 response is defined as a percentage of participants who achieved at least 90% improvement from baseline in the PSSI score. PSSI is a physician assessment of severity of erythema, infiltration, and desquamation and extent of psoriasis involvement. Severity of erythema, infiltration, and desquamation each scored on a scale of 0 (none) to 4 (very severe) and the extent of psoriasis involvement scored on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the psoriasis involvement. The PSSI score ranged from 0 (less severity) to 72 (more severity). Higher scores indicated more severe symptoms. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Week 16
Cohort A: Percentage of Participants Who Achieved IGA Score of Cleared (0) at Week 16
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation; 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.
Time frame: Week 16
Cohort A: Percentage of Participants Who Achieved PASI 100 Response at Week 16
Percentage of participants who achieved PASI-100 response (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Week 16
Cohort A: Percent Change From Baseline in PASI Total Score at Week 16
Percent change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Baseline (Week 0), Week 16
Cohort A: Percent Change From Baseline in Body Surface Area (BSA) at Week 16
A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Baseline (Week 0), Week 16
Cohort A: Time to Greater Than or Equal to (>=) 90 Percent (%) Reduction in PASI Score
Time to \>=90% reduction was defined as the time at which \>=90% improvement in PASI from baseline was achieved. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe and 4=very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: From baseline (Week 0) up to Week 16
Cohorts A and B: Change From Baseline in Total Dermatology Life Quality Index (DLQI) Score at Week 16
Change from baseline in total DLQI score at Week 16 was reported. The DLQI was a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much), where higher score indicated more impact on QoL. The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. Baseline = closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Baseline (Week 0), Week 16
Cohort A: Percentage of Participants Who Achieved >= 4-point Reduction From Baseline in the Psoriasis Symptom and Sign Diary (PSSD) Itch Score at Week 16 Among Participants With Baseline PSSD Itch Score >=4
PSSD was a patient reported outcomes (PRO) questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7 day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Week 16
Cohorts A and B: Change From Baseline in PSSD Symptom Score at Week 16
Change from baseline in PSSD symptoms scores at Week 16 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7-day recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Baseline (Week 0), Week 16
Cohorts A and B: Percentage of Participants Who Achieved PSSD Symptom Score of 0 at Week 16 Among Participants With Baseline PSSD Symptom Score >=1
PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7-day recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Week 16
Cohort B: Percent Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score at Week 16
PSSI is a physician assessment of severity of erythema, infiltration, and desquamation and extent of psoriasis involvement. Severity of erythema, infiltration, and desquamation each scored on a scale of 0 (none) to 4 (very severe) and the extent of psoriasis involvement scored on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the psoriasis involvement. The PSSI score ranged from 0 (less severity) to 72 (more severity). Higher scores indicated more severe symptoms. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Baseline (Week 0), Week 16
Cohort B: Percent Change From Baseline in Scalp Surface Area (SSA) at Week 16
Scalp Surface Area (SSA) is defined as the extent of scalp skin affected by psoriasis, expressed as a percentage of the total scalp surface area. The adult SSA was 520-705 centimeter\^2 (cm\^2), which mean 1% SSA is 5.2 - 7.1 cm\^2. The thumbprint has an average surface area of 5.5 cm\^2 +/- 1.3 cm\^2. The thumb (in particular, the thumb projection) was used as a tool for accurate measurement of 1% SSA. The overall SSA affected by psoriasis was thus be estimated based on the participant's thumb. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Baseline (Week 0), Week 16
Cohort B: Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) at Week 16
The ss-IGA instrument was used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness which was scored as: absence of disease = 0, very mild disease = 1, mild disease = 2, moderate disease = 3, and severe disease = 4. A higher score indicated more severe disease.
Time frame: Week 16
Cohort B: Percentage of Participants Who Achieved PSSI 100 Response at Week 16
PSSI 100 response is defined as a percentage of participants who achieved 100% improvement from baseline in the PSSI score. PSSI is a physician assessment of severity of erythema, infiltration, and desquamation and extent of psoriasis involvement. Severity of erythema, infiltration, and desquamation each scored on a scale of 0 (none) to 4 (very severe) and the extent of psoriasis involvement scored on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the psoriasis involvement. The PSSI score ranged from 0 (less severity) to 72 (more severity). Higher scores indicated more severe symptoms. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Week 16
Cohort B: Time to >=90% Reduction in PSSI Score
Time to \>=90% reduction was defined as the time at which \>=90% improvement in PSSI from baseline was achieved. PSSI is a physician assessment of severity of erythema, infiltration, and desquamation and extent of psoriasis involvement. Severity of erythema, infiltration, and desquamation each scored on a scale of 0 (none) to 4 (very severe) and the extent of psoriasis involvement scored on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the psoriasis involvement. The PSSI score ranged from 0 (less severity) to 72 (more severity). Higher scores indicated more severe symptoms. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: From Baseline (Week 0) up to Week 16
Cohort B: Percentage of Participants Who Achieved >=4-point Reduction From Baseline in the Scalp Itch Numeric Rating Scale (NRS) Score at Week 16 Among Participants With Baseline Scalp Itch Score >=4
The scalp itch NRS was a single-item scale that asks participants to rate the severity of their scalp itching due to psoriasis by considering their worst level of itching over the past 24 hours. The 11-point scalp itch NRS ranged from 0 (no scalp itch) to 10 (worst scalp itch imaginable). Higher scores indicated more severe scalp itch. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
Time frame: Week 16
Cohorts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAE was defined as any AE that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.
Time frame: Cohorts A and B: Placebo: From Week 0 to Week 16; Cohorts A and B: Placebo Followed by Guselkumab 100 mg: From Week 16 to Week 112; Cohorts A and B: Guselkumab 100 mg: From Week 0 to Week 112
Cohorts A and B: Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)
An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any AE that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.
Time frame: Cohorts A and B: Placebo: From Week 0 to Week 16; Cohorts A and B: Placebo Followed by Guselkumab 100 mg: From Week 16 to Week 112; Cohorts A and B: Guselkumab 100 mg: From Week 0 to Week 112
| Milestone | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|---|---|
| Started | 26 | 77 | 27 | 81 |
| Participants who crossed over to guselkumab | 25 | 0 | 24 | 0 |
| Completed | 22 | 67 | 20 | 77 |
| Not completed | 4 | 10 | 7 | 4 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 6 | 3 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 3 | 4 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation; 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.
| Percentage of participants | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg |
|---|---|---|
| Cohort A: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 | 0 | 74.0 |
Percentage of participants who achieved PASI 90 response (greater than or equal to \[\>=\] 90 percent \[%\] improvement from baseline in PASI) at Week 16 was reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe and 4=very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percentage of participants | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg |
|---|---|---|
| Cohort A: Percentage of Participants Who Achieved Psoriasis Area Severity Index (PASI) 90 Response at Week 16 | 3.8 | 57.1 |
The ss-IGA instrument was used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness which was scored as: absence of disease = 0, very mild disease = 1, mild disease = 2, moderate disease = 3, and severe disease = 4. A higher score indicated more severe disease.
| Percentage of participants | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|
| Cohort B: Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) or Very Mild Disease (1) at Week 16 | 11.5 | 68.4 |
PSSI 90 response is defined as a percentage of participants who achieved at least 90% improvement from baseline in the PSSI score. PSSI is a physician assessment of severity of erythema, infiltration, and desquamation and extent of psoriasis involvement. Severity of erythema, infiltration, and desquamation each scored on a scale of 0 (none) to 4 (very severe) and the extent of psoriasis involvement scored on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the psoriasis involvement. The PSSI score ranged from 0 (less severity) to 72 (more severity). Higher scores indicated more severe symptoms. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percentage of participants | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|
| Cohort B: Percentage of Participants Who Achieved Psoriasis Scalp Severity Index (PSSI) 90 Response at Week 16 | 3.8 | 65.8 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation; 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.
| Percentage of participants | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg |
|---|---|---|
| Cohort A: Percentage of Participants Who Achieved IGA Score of Cleared (0) at Week 16 | 0 | 32.5 |
Percentage of participants who achieved PASI-100 response (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percentage of participants | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg |
|---|---|---|
| Cohort A: Percentage of Participants Who Achieved PASI 100 Response at Week 16 | 0 | 29.9 |
Percent change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percent change | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg |
|---|---|---|
| Cohort A: Percent Change From Baseline in PASI Total Score at Week 16 | -8.30 (-19.04 to 2.45) | -84.49 (-90.89 to -78.09) |
A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percent change | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg |
|---|---|---|
| Cohort A: Percent Change From Baseline in Body Surface Area (BSA) at Week 16 | -0.94 (-15.49 to 13.60) | -77.92 (-86.72 to -69.12) |
Time to \>=90% reduction was defined as the time at which \>=90% improvement in PASI from baseline was achieved. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe and 4=very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Weeks | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg |
|---|---|---|
| Cohort A: Time to Greater Than or Equal to (>=) 90 Percent (%) Reduction in PASI Score | NA (NA to NA) | 13.2 (8.4 to NA) |
Change from baseline in total DLQI score at Week 16 was reported. The DLQI was a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much), where higher score indicated more impact on QoL. The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. Baseline = closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Units on a Scale | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|---|---|
| Cohorts A and B: Change From Baseline in Total Dermatology Life Quality Index (DLQI) Score at Week 16 | -2.48 (-4.39 to -0.56) | -12.06 (-13.22 to -10.91) | -2.16 (-4.76 to 0.44) | -9.66 (-11.09 to -8.23) |
PSSD was a patient reported outcomes (PRO) questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7 day recall version was used. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. PSSD itch item score over seven days was averaged into a weekly itch score, ranging from 0 to 10 with higher scores indicating severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percentage of participants | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg |
|---|---|---|
| Cohort A: Percentage of Participants Who Achieved >= 4-point Reduction From Baseline in the Psoriasis Symptom and Sign Diary (PSSD) Itch Score at Week 16 Among Participants With Baseline PSSD Itch Score >=4 | 16.7 | 66.7 |
Change from baseline in PSSD symptoms scores at Week 16 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7-day recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Units on a scale | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|---|---|
| Cohorts A and B: Change From Baseline in PSSD Symptom Score at Week 16 | -8.19 (-15.76 to -0.62) | -49.45 (-53.98 to -44.92) | -8.28 (-18.42 to 1.87) | -44.81 (-50.53 to -39.09) |
PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. 7-day recall version was used. PSSD was self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the weekly symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percentage of participants | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|---|---|
| Cohorts A and B: Percentage of Participants Who Achieved PSSD Symptom Score of 0 at Week 16 Among Participants With Baseline PSSD Symptom Score >=1 | 0 | 10.4 | 3.8 | 21.3 |
PSSI is a physician assessment of severity of erythema, infiltration, and desquamation and extent of psoriasis involvement. Severity of erythema, infiltration, and desquamation each scored on a scale of 0 (none) to 4 (very severe) and the extent of psoriasis involvement scored on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the psoriasis involvement. The PSSI score ranged from 0 (less severity) to 72 (more severity). Higher scores indicated more severe symptoms. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percent change | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|
| Cohort B: Percent Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score at Week 16 | -37.79 (-48.09 to -27.49) | -87.62 (-93.42 to -81.81) |
Scalp Surface Area (SSA) is defined as the extent of scalp skin affected by psoriasis, expressed as a percentage of the total scalp surface area. The adult SSA was 520-705 centimeter\^2 (cm\^2), which mean 1% SSA is 5.2 - 7.1 cm\^2. The thumbprint has an average surface area of 5.5 cm\^2 +/- 1.3 cm\^2. The thumb (in particular, the thumb projection) was used as a tool for accurate measurement of 1% SSA. The overall SSA affected by psoriasis was thus be estimated based on the participant's thumb. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percent change | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|
| Cohort B: Percent Change From Baseline in Scalp Surface Area (SSA) at Week 16 | -33.40 (-45.69 to -21.11) | -86.56 (-93.46 to -79.67) |
The ss-IGA instrument was used to evaluate the disease severity of scalp psoriasis. The lesions were assessed in terms of the clinical signs of redness, thickness, and scaliness which was scored as: absence of disease = 0, very mild disease = 1, mild disease = 2, moderate disease = 3, and severe disease = 4. A higher score indicated more severe disease.
| Percentage of participants | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|
| Cohort B: Percentage of Participants Who Achieved Scalp Specific (ss)-IGA Score of Absence of Disease (0) at Week 16 | 3.8 | 57.9 |
PSSI 100 response is defined as a percentage of participants who achieved 100% improvement from baseline in the PSSI score. PSSI is a physician assessment of severity of erythema, infiltration, and desquamation and extent of psoriasis involvement. Severity of erythema, infiltration, and desquamation each scored on a scale of 0 (none) to 4 (very severe) and the extent of psoriasis involvement scored on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the psoriasis involvement. The PSSI score ranged from 0 (less severity) to 72 (more severity). Higher scores indicated more severe symptoms. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percentage of participants | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|
| Cohort B: Percentage of Participants Who Achieved PSSI 100 Response at Week 16 | 3.8 | 59.2 |
Time to \>=90% reduction was defined as the time at which \>=90% improvement in PSSI from baseline was achieved. PSSI is a physician assessment of severity of erythema, infiltration, and desquamation and extent of psoriasis involvement. Severity of erythema, infiltration, and desquamation each scored on a scale of 0 (none) to 4 (very severe) and the extent of psoriasis involvement scored on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the psoriasis involvement. The PSSI score ranged from 0 (less severity) to 72 (more severity). Higher scores indicated more severe symptoms. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Weeks | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|
| Cohort B: Time to >=90% Reduction in PSSI Score | NA (NA to NA) | 11.6 (6.0 to 15.3) |
The scalp itch NRS was a single-item scale that asks participants to rate the severity of their scalp itching due to psoriasis by considering their worst level of itching over the past 24 hours. The 11-point scalp itch NRS ranged from 0 (no scalp itch) to 10 (worst scalp itch imaginable). Higher scores indicated more severe scalp itch. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date unless otherwise specified.
| Percentage of participants | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|
| Cohort B: Percentage of Participants Who Achieved >=4-point Reduction From Baseline in the Scalp Itch Numeric Rating Scale (NRS) Score at Week 16 Among Participants With Baseline Scalp Itch Score >=4 | 24.0 | 69.4 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAE was defined as any AE that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.
| Participants | Cohort A: Placebo | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|---|---|---|---|
| Cohorts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 5 | 13 | 58 | 3 | 11 | 63 |
An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any AE that occurred after the start of initial study agent administration and those AEs that were presented at baseline but worsened in severity after the start of initial study agent administration.
| Participants | Cohort A: Placebo | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|---|---|---|---|
| Cohorts A and B: Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) | 0 | 1 | 3 | 1 | 0 | 3 |
Collected over Cohorts A and B: Placebo: From Week 0 to Week 16, Cohorts A and B: Placebo Followed by Guselkumab 100 mg: From Week 16 to Week 112, Cohorts A and B: Guselkumab 100 mg: From Week 0 to Week 112. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: Placebo | 0/26 (0%) | 0/26 (0%) | 5/26 (19.2%) |
| Cohort A: Placebo Followed by Guselkumab 100 mg | 0/25 (0%) | 1/25 (4%) | 8/25 (32%) |
| Cohort A: Guselkumab 100 mg | 0/77 (0%) | 3/77 (3.9%) | 36/77 (46.8%) |
| Cohort B: Placebo | 0/27 (0%) | 1/27 (3.7%) | 2/27 (7.4%) |
| Cohort B: Placebo Followed by Guselkumab 100 mg | 0/24 (0%) | 0/24 (0%) | 8/24 (33.3%) |
| Cohort B: Guselkumab 100 mg | 0/81 (0%) | 3/81 (3.7%) | 43/81 (53.1%) |
| Event | Cohort A: Placebo | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/26 | 1/25 | 0/77 | 0/27 | 0/24 | 0/81 |
| Viral RashInfections and infestations | 0/26 | 0/25 | 0/77 | 1/27 | 0/24 | 0/81 |
| Perforation Bile DuctHepatobiliary disorders | 0/26 | 0/25 | 1/77 | 0/27 | 0/24 | 0/81 |
| AppendicitisInfections and infestations | 0/26 | 0/25 | 1/77 | 0/27 | 0/24 | 0/81 |
| Gallbladder AbscessInfections and infestations | 0/26 | 0/25 | 1/77 | 0/27 | 0/24 | 0/81 |
| PyelonephritisInfections and infestations | 0/26 | 0/25 | 1/77 | 0/27 | 0/24 | 0/81 |
| Angina PectorisCardiac disorders | 0/26 | 0/25 | 0/77 | 0/27 | 0/24 | 1/81 |
| PancreatitisGastrointestinal disorders | 0/26 | 0/25 | 0/77 | 0/27 | 0/24 | 1/81 |
| PneumoniaInfections and infestations | 0/26 | 0/25 | 0/77 | 0/27 | 0/24 | 1/81 |
| Event | Cohort A: Placebo | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg |
|---|---|---|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 1/26 | 1/25 | 13/77 | 1/27 | 6/24 | 20/81 |
| Covid-19Infections and infestations | 0/26 | 0/25 | 5/77 | 0/27 | 1/24 | 13/81 |
| NasopharyngitisInfections and infestations | 1/26 | 2/25 | 9/77 | 0/27 | 1/24 | 6/81 |
| HypertensionVascular disorders | 3/26 | 0/25 | 5/77 | 0/27 | 0/24 | 2/81 |
| Food PoisoningGastrointestinal disorders | 0/26 | 0/25 | 0/77 | 0/27 | 2/24 | 1/81 |
| MigraineNervous system disorders | 0/26 | 0/25 | 1/77 | 0/27 | 2/24 | 0/81 |
| Tooth AbscessInfections and infestations | 0/26 | 2/25 | 0/77 | 0/27 | 0/24 | 0/81 |
| Aspartate Aminotransferase IncreasedInvestigations | 0/26 | 2/25 | 1/77 | 0/27 | 1/24 | 0/81 |
| PruritusSkin and subcutaneous tissue disorders | 0/26 | 2/25 | 1/77 | 0/27 | 0/24 | 0/81 |
| Type 2 Diabetes MellitusMetabolism and nutrition disorders | 0/26 | 0/25 | 4/77 | 0/27 | 0/24 | 6/81 |
| Age, Categorical(Participants) | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 22 | 75 | 27 | 77 | 201 |
| >=65 years | 4 | 2 | 0 | 4 | 10 |
| Sex: Female, Male(Participants) | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg | Total |
|---|---|---|---|---|---|
| Female | 7 | 22 | 8 | 38 | 75 |
| Male | 19 | 55 | 19 | 43 | 136 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 40 | 9 | 33 | 94 |
| Not Hispanic or Latino | 14 | 37 | 18 | 48 | 117 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 8 | 16 | 12 | 27 | 63 |
| Black or African American | 2 | 9 | 3 | 10 | 24 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 1 | 4 | 2 | 5 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Other | 14 | 48 | 10 | 38 | 110 |
| Age, Continuous(Years) | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg | Total |
|---|---|---|---|---|---|
| Mean | 42.3 ± 15.73 | 44.7 ± 11.8 | 41 ± 12.82 | 43.3 ± 13.58 | 43.4 ± 13.11 |
| Region of Enrollment(Participants) | Cohort A: Placebo Followed by Guselkumab 100 mg | Cohort A: Guselkumab 100 mg | Cohort B: Placebo Followed by Guselkumab 100 mg | Cohort B: Guselkumab 100 mg | Total |
|---|---|---|---|---|---|
| CANADA | 9 | 24 | 12 | 30 | 75 |
| UNITED STATES | 17 | 53 | 15 | 51 | 136 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Jul 2022 to primary completion in May 2025, 34 months.
Results were first posted in Jun 2026, 1 year after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 34 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →